You are here » Home » Companies » Company Overview » SMS Lifesciences India Ltd

SMS Lifesciences India Ltd.

BSE: 540679	Sector: Health care
NSE: SMSLIFE	ISIN Code: INE320X01016

BSE 00:00 | 24 Mar

533.00

-12.00
(-2.20%)

OPEN

549.95

HIGH

550.00

LOW

533.00

NSE 00:00 | 24 Mar

533.20

-12.00
(-2.20%)

OPEN

536.05

HIGH

540.10

LOW

532.00

Add to Watchlist | Add to Portfolio

OPEN	549.95
PREVIOUS CLOSE	545.00
VOLUME	113
52-Week high	947.75
52-Week low	501.00
P/E	10.72
Mkt Cap.(Rs cr)	161
Buy Price	0.00
Buy Qty	0.00
Sell Price	0.00
Sell Qty	0.00

OPEN	549.95
CLOSE	545.00
VOLUME	113
52-Week high	947.75
52-Week low	501.00
P/E	10.72
Mkt Cap.(Rs cr)	161
Buy Price	0.00
Buy Qty	0.00
Sell Price	0.00
Sell Qty	0.00

SMS Lifesciences India Ltd. (SMSLIFE) - News Sector

Zydus Lifesciences gets US health regulator's nod for its generic medicine

3.04 pm | 24 Mar 2023 | Press Trust of India

Zydus Lifesciences Ltd on Friday said it has received final approval from the US health regulator for its generic doxepin hydrochloride capsules used ...
Multiple triggers likely to help Zydus to continue with its outperformance

11.14 pm | 23 Mar 2023 | Business Standard

New launches in the US, market share gains and steady domestic growth are positives
Fight over control of Hikal: Hiremath, family move HC against Baba Kalyani

10.40 pm | 23 Mar 2023 | Business Standard

Hikal said it did not expect any financial implications arising due to compensation, penalty, etc, due to the suit
India's e-comm mkt to grow from $83 bn in 2022 to $185 bn in 2026: Report

5.03 pm | 23 Mar 2023 | Business Standard

UPI driving consumers away from cash and helping financial inclusion, it says
Glenmark gets USFDA nod to market generic medication to treat schizophrenia

11.53 am | 20 Mar 2023 | Press Trust of India

Glenmark Pharmaceuticals on Monday said it has received approval from the US health regulator to market a generic product used to treat schizophrenia ...
India was world's No. 1 in handling Covid: Apollo Hospitals founder

10.54 pm | 19 Mar 2023 | Business Standard

In a Q&A, Prathap Chandra Reddy talks about the need to focus on medical tourism and medical education to meet the demand of 18 million professionals ...
Eris down 4% in 2 days post acquisition of 9 derma brands from Dr Reddy's

10.47 am | 17 Mar 2023 | Business Standard

Eris Life said that the transaction would help augment and expand cosmetic dermatology business of the company through their product offerings
Eris down 4% in 2 days post acquisition of 9 derma brands from Dr Reddy's

10.47 am | 17 Mar 2023 | Business Standard

Eris Life said that the transaction would help augment and expand cosmetic dermatology business of the company through their product offerings
Eris Lifesciences buys dermatology brands from Dr Reddy's for Rs 275 crore

11.30 pm | 16 Mar 2023 | Business Standard

In January Eris had bought some derma brands from Glenmark Pharma as well
RIL, Mphasis: 45 stocks hit fresh 52-week lows; charts show more pain ahead

11.35 am | 15 Mar 2023 | Business Standard

The heavy-weight Reliance Industries has broken critical support of Rs 2,300, raising concerns about the future drawdown. In addition, the formation r...
RIL, Mphasis: 45 stocks hit fresh 52-week lows; charts show more pain ahead

11.35 am | 15 Mar 2023 | Business Standard

The heavy-weight Reliance Industries has broken critical support of Rs 2,300, raising concerns about the future drawdown. In addition, the formation r...
RIL, Mphasis: 45 stocks hit fresh 52-week lows; charts show more pain ahead

11.35 am | 15 Mar 2023 | Business Standard

The heavy-weight Reliance Industries has broken critical support of Rs 2,300, raising concerns about the future drawdown. In addition, the formation r...
RIL, Mphasis: 45 stocks hit fresh 52-week lows; charts show more pain ahead

11.35 am | 15 Mar 2023 | Business Standard

The heavy-weight Reliance Industries has broken critical support of Rs 2,300, raising concerns about the future drawdown. In addition, the formation r...
Nifty Pharma index hits 2-year low; Cipla, Divis, Laurus Labs at 52-wk lows

2.25 pm | 14 Mar 2023 | Business Standard

Analysts said the pace of US FDA inspections has again picked-up in the last few months post Covid, and they have seen increased incidents with 483 ob...
Nifty Pharma index hits 2-year low; Cipla, Divis, Laurus Labs at 52-wk lows

2.25 pm | 14 Mar 2023 | Business Standard

Analysts said the pace of US FDA inspections has again picked-up in the last few months post Covid, and they have seen increased incidents with 483 ob...
Nifty Pharma index hits 2-year low; Cipla, Divis, Laurus Labs at 52-wk lows

2.25 pm | 14 Mar 2023 | Business Standard

Analysts said the pace of US FDA inspections has again picked-up in the last few months post Covid, and they have seen increased incidents with 483 ob...
Nifty Pharma index hits 2-year low; Cipla, Divis, Laurus Labs at 52-wk lows

2.25 pm | 14 Mar 2023 | Business Standard

Analysts said the pace of US FDA inspections has again picked-up in the last few months post Covid, and they have seen increased incidents with 483 ob...
Nifty Pharma index hits 2-year low; Cipla, Divis, Laurus Labs at 52-wk lows

2.25 pm | 14 Mar 2023 | Business Standard

Analysts said the pace of US FDA inspections has again picked-up in the last few months post Covid, and they have seen increased incidents with 483 ob...
Nifty Pharma index hits 2-year low; Cipla, Divis, Laurus Labs at 52-wk lows

2.25 pm | 14 Mar 2023 | Business Standard

Analysts said the pace of US FDA inspections has again picked-up in the last few months post Covid, and they have seen increased incidents with 483 ob...
Glenmark Pharma receives USFDA approval for generic antibiotic drug

2.19 pm | 14 Mar 2023 | Press Trust of India

Glenmark Pharmaceuticals on Tuesday said it has received approval from the US health regulator to market a generic antibiotic drug. The company has r...